BioNTech Investor Presentation Deck

Selected 2022 Pipeline Milestones COVID-19 vaccine: Follow on and Next Gen Vaccines 4 Infectious Disease First-In-Human Trial Starts 4 Oncology First-in- Human Trial Starts 26 3 Data Updates Milestones Omicron BA.4/5-adapted bivalent vaccine trial start BNT162b5: Next-generation bivalent vaccine, enhanced SARS-CoV-2 encoding ancestral and BA.2 spike antigen T cell enhancing vaccine trial start Additional next-generation vaccine trial starts, including pan-SARS-CoV-2 vaccine Multiple data updates Shingles vaccine ¹ BNT163 HSV2 vaccine BNT164 tuberculosis vaccine² BNT 165 malaria vaccine BNT141 RiboMab in solid tumors (CLDN18.2) BNT142 RiboMab in solid tumors (CD3×CLDN6) BNT116 FixVac in combo with Cemiplimab in NSCLC BNT313 (GEN1053) in solid tumors³ BNT 161 influenza mRNA vaccine ¹ BNT1224 Phase 2 iNeST in combo with Pembro in frontline melanoma BNT211 Phase 1/2 CAR-T/CLDN6+ in multiple solid tumors HSV 2, Herpes simplex virus type 2; FPD, first patient dosed; CLDN, Claudin; NSCLC, non-small cell lung cancer 1 Partnered with Pfizer; 2 Collaboration with BMGF; 3 Collaboration with Genmab 4 Partnered with Genentech Anticipated Timing August 2022 Phase 2: FPD July 2022 2H 2022 2H 2022 2H 2022 2H 2022 2H 2022 2H 2022 / early 2023 2H 2022 / early 2023 FPD in Jan. 2022 FPD in July 2022 FPD in July 2022 2H 2022 July 2022 now in 1H 2023 2H 2022 BIONTECH

View entire presentation